Gelonghui November 4th | hybio pharmaceutical (300199.SZ) stated on the investor interaction platform that on October 30, the company's Lirarutan peptide injection received a large-scale shipment, with a total value of 0.103 billion yuan, which is a commercial bulk order announced by the company on November 3, 2023. In the future, the company will maintain a long-term exclusive partnership with Hikma according to the agreement, continue to advance subsequent order shipments based on the demand in the USA sales market, and receive double-digit sales profit sharing. In addition to this order, the company will gradually issue subsequent orders according to the progress of the project. Please pay attention to the company's public information on the fulfillment of future orders.